title: MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
abstract: OBJECTIVE
  The purpose of the present study was to evaluate the antitumor activity and pharmacokinetic profile of MEN4901/T-0128 in nude mice bearing human tumor xenografts in comparison with irinotecan (CPT-11) and T-2513.
  
  
  METHODS
  We have determined the antitumor activity of MEN4901/T-0128, CPT-11, and T-2513 in BALB/cA Jcl nude mice bearing human gastric (H-81), colon (H-110), lung (Mqnu-1, H-74), esophageal (H-204), liver (H-181), and pancreatic (H-48) cancer lines, which had been serially transplanted s.c. and maintained in nude mice, and characterized the pharmacokinetic profile of MEN4901/T-0128 in nude mice bearing human gastric carcinoma St-4.
  
  
  RESULTS
  MEN4901/T-0128 administered i.v. showed a marked antitumor activity in each of these tumor models, producing tumor shrinkage in the models of H-204 and H-181 carcinomas at its maximum tolerated dose of 80 mg/kg (expressed as T-2513) weekly for 4 weeks (q7d x 4) and tumor-shrinking or marked growth-inhibitory effects in the models of H-81, H-110, Mqnu-1, H-74, and H-48 carcinomas at 1/3 of its maximum tolerated dose (q7d x 4). Pharmacokinetic analysis showed that MEN4901/T-0128 had an extended plasma half-life with sustained tumor levels of T-2513, which may explain the superior activity of MEN4901/T-0128 in vivo.
  
  
  CONCLUSIONS
  Because the efficacies of some drugs in this human cancer-nude mouse panel correlated well with their clinical outcomes in patients with the same type of cancers, the findings provide direct support that MEN4901/T-0128 is more efficacious than CPT-11 and is an excellent candidate for clinical trials for the treatment of solid tumors.
authors.affiliation: Experimental Cancer Chemotherapy Research Laboratories Co., Ltd, Osaka University, Osaka, Japan.
authors.forename: Fumiko
authors.initials: F
authors.lastname: Fujita
authors.forename: Masako
authors.initials: M
authors.lastname: Koike
authors.forename: Masahide
authors.initials: M
authors.lastname: Fujita
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Okuno
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yano
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yano
authors.forename: Satoko
authors.initials: S
authors.lastname: Kiuchi
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Shinzoh
authors.initials: S
authors.lastname: Kudoh
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kakushima
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D001835:Body Weight / Q000187:drug effects; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D003911:Dextrans / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D013997:Time Factors; D019772:Topotecan / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D003911:Dextrans; D000077146:Irinotecan; D019772:Topotecan; C410031:T 0128; D002166:Camptothecin